United Kingdom Prospective Diabetes Study: Implications for metformin

Clifford J. Bailey*, Ian W. Campbell

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


One of the purposes of the United Kingdom Prospective Diabetes Study (UKPDS) was to compare the efficacy of different antidiabetic drugs in the long-term treatment of type 2 diabetes. In overweight type 2 patients, use of metformin as the initial antidiabetic drug therapy reduced overall mortality and reduced various long-term complications to a greater extent than other first-line treatments tested (sulphonylureas and insulin) whilst controlling hyperglycaemia to a similar extent. The benefit of early intervention with metformin may be due, at least in part, to its actions against insulin resistance and associated cardiovascular risk factors. Thus the UKPDS has provided evidence that early intensive glucose control with metformin in overweight type 2 diabetic patients is a particularly effective approach to reduce vascular complications and improve survival.

Original languageEnglish
Pages (from-to)115-119
Number of pages5
JournalBritish Journal of Cardiology
Issue number2
Publication statusPublished - 1 Jan 2002


  • Complications
  • Insulin resistance
  • Metformin
  • Survival
  • Type 2 diabetes


Dive into the research topics of 'United Kingdom Prospective Diabetes Study: Implications for metformin'. Together they form a unique fingerprint.

Cite this